Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
Authors
Keywords
-
Journal
Expert Review of Respiratory Medicine
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2018-12-31
DOI
10.1080/17476348.2019.1563488
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma
- (2018) Shingo Inaguma et al. HUMAN PATHOLOGY
- Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.
- (2018) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma
- (2018) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma
- (2018) Fausto Petrelli et al. RESPIRATORY MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
- (2018) Anna K. Nowak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).
- (2018) Arpita Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma
- (2018) Surein Arulananda et al. Journal of Thoracic Oncology
- Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection
- (2018) Vivek Verma et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Prospect of rindopepimut in the treatment of glioblastoma
- (2017) Aladine A. Elsamadicy et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
- (2017) Raffit Hassan et al. Journal of Thoracic Oncology
- MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
- (2017) Y. Goto et al. Journal of Thoracic Oncology
- OA13.02 Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis
- (2017) Hedy Kindler et al. Journal of Thoracic Oncology
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Amatuximab and novel agents targeting mesothelin for solid tumors
- (2017) Paolo Baldo et al. OncoTargets and Therapy
- Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
- (2017) Takashi Eguchi et al. Oncotarget
- The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
- (2017) Christian M. Schürch et al. OncoImmunology
- Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
- (2016) Robin Cornelissen et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
- (2016) Jae H. Park et al. BLOOD
- CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor
- (2016) Silvio Roncella et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN Combined with Chemotherapy
- (2016) D. H. Sterman et al. CLINICAL CANCER RESEARCH
- Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas
- (2016) Christelle Combaz-Lair et al. HUMAN PATHOLOGY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Malignant Mesothelioma Effusions Are Infiltrated by CD3 + T Cells Highly Expressing PD-L1 and the PD-L1 + Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab
- (2016) Swati Khanna et al. Journal of Thoracic Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
- (2016) M. M. Awad et al. Cancer Immunology Research
- Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
- (2016) Elly Marcq et al. OncoImmunology
- Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
- (2016) Tuuli Ranki et al. Journal for ImmunoTherapy of Cancer
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study
- (2015) Marco Lo Iacono et al. Journal of Thoracic Oncology
- Intratumoral macrophage phenotype and CD8 + T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma
- (2015) Robin Cornelissen et al. LUNG CANCER
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Reactive oxygen species a double-edged sword for mesothelioma
- (2015) Serena Benedetti et al. Oncotarget
- CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
- (2015) Luis H. Camacho Cancer Medicine
- Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
- (2015) Luana Calabrò et al. Lancet Respiratory Medicine
- Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen
- (2015) Jenette Creaney et al. OncoImmunology
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
- (2015) Susana Cedrés et al. PLoS One
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
- (2014) M. Rajasagi et al. BLOOD
- Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
- (2014) G. Guo et al. CANCER RESEARCH
- Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
- (2014) R. Hassan et al. CLINICAL CANCER RESEARCH
- B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
- (2014) Aaron Scott Mansfield et al. Journal of Thoracic Oncology
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
- (2014) Mahesh Yadav et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
- (2014) Robin Cornelissen et al. PLoS One
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer
- (2013) Darin A. Wick et al. CLINICAL CANCER RESEARCH
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation
- (2012) B. M. Burt et al. CLINICAL CANCER RESEARCH
- Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma
- (2011) Bryan M. Burt et al. CANCER
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
- (2011) Caroline J. Breitbach et al. NATURE
- The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
- (2011) Matthew Bott et al. NATURE GENETICS
- Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma
- (2010) Joost P. Hegmans et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
- (2010) H Li et al. CANCER GENE THERAPY
- WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
- (2010) Lee M. Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
- (2010) Vincenzo Cerullo et al. CANCER RESEARCH
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
- (2010) Anniina Koski et al. MOLECULAR THERAPY
- Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma
- (2009) Marc de Perrot et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma
- (2009) Lee M. Krug et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy
- (2009) Servet Bölükbas et al. LUNG CANCER
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response
- (2008) A. Gauvrit et al. CANCER RESEARCH
- Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
- (2008) Masaki Anraku et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Pathology of mesothelioma
- (2008) Kouki Inai Environmental Health and Preventive Medicine
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started